

Contents

	Introduction	12
	Epidemiology	14
	Pathogenesis	18
	Clinical picture	20
	Diagnostics	24
5.1.	Imaging techniques.....	24
5.2.	Biopsy and histopathology.....	26
5.3.	Neurocognitive evaluation.....	27
5.4.	Staging.....	30
5.4.1.	Lumbar puncture.....	30
5.4.2.	Ophthalmic examination.....	31
5.4.3.	Bone marrow biopsy.....	32
5.5.	Further investigations.....	32
	Prognostic factors	36
	Therapy	38
7.1.	Criteria for assessing the therapy response.....	38
7.2.	Therapeutic principles.....	39
7.3.	Induction therapy.....	40
7.3.1.	Methotrexate-based chemotherapy regimens.....	40
7.3.2.	Methotrexate-based polychemotherapy.....	40
7.4.	Consolidation strategies.....	41
7.4.1.	High-dose chemotherapy and autologous stem-cell transplantation (HDC/ASCT).....	41
7.4.2.	Intensive conventional chemotherapy without ASCT.....	42
7.4.3.	Radiotherapy.....	42
7.4.4.	Maintenance treatment.....	43
7.5.	Therapy in relapse or refractory disease.....	44
7.5.1.	Renewed chemotherapy for recurrent PCNSL.....	44
7.5.2.	HDC/ASCT.....	45
7.5.3.	Palliative radiotherapy.....	45
	New drug substances	48
8.1.	Lenalidomide.....	48
8.2.	Ibrutinib.....	48
8.3.	mTOR inhibition.....	49
8.4.	PD-1 targeted therapy.....	49

	Therapy for special patient groups	52
9.1.	Elderly patients	52
9.2.	Immunosuppressed patients	52
9.3.	Patients with ocular infestation	53
9.4.	Patients with leptomenigeal infestation	53
9.5.	Patients with kidney failure (without MTX)	53
	Supportive therapies	56
10.1.	Steroid medication	56
10.2.	Prophylaxis against infections	56
10.3.	Prophylaxis for epileptic seizures	56
10.4.	Physiotherapy and rehabilitation	56
	Risks of toxicity	58
11.1.	Criteria for toxicity	58
11.2.	Organ toxicity	58
11.3.	Infections	58
11.4.	Leukoencephalopathy	58
	Aftercare	60
	Summary and outlook	62
	References	64
	Abbreviations	74
	Index	76